Today, FBR & Co Research Analysts Lift Earnings Estimates for TG Therapeutics Inc. (TGTX)

Today, FBR & Co Research Analysts Lift Earnings Estimates for TG Therapeutics Inc. (TGTX)

TG Therapeutics Inc. (NASDAQ:TGTX) – Analysts at FBR & Co boosted their FY2017 earnings estimates for TG Therapeutics in a research report issued to clients and investors on Thursday. FBR & Co analyst E. White now expects that the firm will earn ($1.16) per share for the year, up from their previous forecast of ($1.25). FBR & Co has a “Buy” rating on the stock. FBR & Co also issued estimates for TG Therapeutics’ FY2018 earnings at ($1.41) EPS.

A number of other research analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $18.00 price target (down from $22.00) on shares of TG Therapeutics in a report on Saturday. Ladenburg Thalmann reissued a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a report on Saturday. Roth Capital reissued a “buy” rating and issued a $33.00 price target on shares of TG Therapeutics in a report on Friday. Brean Capital reissued a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a report on Thursday, October 6th. Finally, S&P Equity Research decreased their price target on TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $21.21.

TG Therapeutics (NASDAQ:TGTX) traded up 3.33% on Monday, hitting $6.21. 47,959 shares of the company were exchanged. The stock’s market capitalization is $338.17 million. TG Therapeutics has a 52-week low of $5.41 and a 52-week high of $14.87. The stock’s 50-day moving average price is $7.38 and its 200-day moving average price is $7.33.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%.

Hedge funds have recently modified their holdings of the company. Bridger Management LLC purchased a new stake in shares of TG Therapeutics during the first quarter valued at approximately $28,503,000. Pictet Asset Management Ltd. boosted its stake in shares of TG Therapeutics by 753.5% in the second quarter. Pictet Asset Management Ltd. now owns 1,215,449 shares of the biopharmaceutical company’s stock valued at $9,140,000 after buying an additional 1,073,049 shares during the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of TG Therapeutics by 30.0% in the first quarter. UBS Asset Management Americas Inc. now owns 2,021,310 shares of the biopharmaceutical company’s stock valued at $17,223,000 after buying an additional 466,193 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 11.5% in the second quarter. Vanguard Group Inc. now owns 1,484,133 shares of the biopharmaceutical company’s stock valued at $8,995,000 after buying an additional 152,700 shares during the last quarter. Finally, Opaleye Management Inc. boosted its stake in shares of TG Therapeutics by 38.3% in the first quarter. Opaleye Management Inc. now owns 415,000 shares of the biopharmaceutical company’s stock valued at $3,536,000 after buying an additional 115,000 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About TG Therapeutics

Related posts

Leave a Comment